{
  "@context": {
    "biotools": "https://bio.tools/ontology/",
    "bsc": "http://bioschemas.org/",
    "bsct": "http://bioschemas.org/types/",
    "dct": "http://purl.org/dc/terms/",
    "edam": "http://edamontology.org/",
    "owl": "http://www.w3.org/2002/07/owl#",
    "rdf": "http://www.w3.org/1999/02/22-rdf-syntax-ns#",
    "rdfs": "http://www.w3.org/2000/01/rdf-schema#",
    "sc": "http://schema.org/",
    "xsd": "http://www.w3.org/2001/XMLSchema#"
  },
  "@graph": [
    {
      "@id": "https://bio.tools/tide",
      "@type": "sc:SoftwareApplication",
      "dct:conformsTo": "https://bioschemas.org/profiles/ComputationalTool/0.6-DRAFT",
      "sc:applicationSubCategory": [
        {
          "@id": "edam:topic_3170"
        },
        {
          "@id": "edam:topic_0203"
        },
        {
          "@id": "edam:topic_2640"
        },
        {
          "@id": "edam:topic_3360"
        },
        {
          "@id": "edam:topic_3379"
        }
      ],
      "sc:citation": [
        "pubmed:32102694",
        {
          "@id": "https://doi.org/10.1186/S13073-020-0721-Z"
        },
        "pmcid:PMC7045518"
      ],
      "sc:description": "Large-scale public data reuse to model immunotherapy response and resistance.\n\nTumor Immune Dysfunction and Exclusion (TIDE).\n\nWe validated TIDE performance on predicting anti-PD1 and anti-CTLA4 response across several melanoma datasets and a limited dataset of non-small cell lung cancer (NSCLC). TIDE may not work on cancer types other than melanoma and NSCLC (e.g., glioblastoma, or renal cell carcinoma) and therapies other than anti-PD1 and anti-CTLA4 (e.g., anti-PDL1, or Car T).",
      "sc:featureList": [
        {
          "@id": "edam:operation_2495"
        },
        {
          "@id": "edam:operation_3435"
        }
      ],
      "sc:name": "TIDE",
      "sc:url": "http://tide.dfci.harvard.edu"
    },
    {
      "@id": "https://doi.org/10.1186/S13073-020-0721-Z",
      "@type": "sc:CreativeWork"
    }
  ]
}